Coiled Therapeutics (LSE:COIL) is listed among the constituents of the FTSE AIM All Share Index, and is one of the less familiar names in the life sciences segment of London's growth market. As its name indicates, the company is positioned in the therapeutics space, where value is typically built through scientific progress, clinical milestones and commercial partnerships rather than near-term revenue.
What the company does
Coiled Therapeutics is a therapeutics-focused company quoted on AIM. Businesses in this field typically work on a technology platform or a pipeline of drug candidates aimed at specific diseases, advancing them through preclinical work and clinical trials before seeking regulatory approval or a partner to take a product to market. The value of such a company rests on the quality of its science, the size of the medical need it addresses and its ability to fund development through to key data points. Its annual report, admission documents and website set out what it owns and what it is developing.
Latest developments
For a therapeutics company on AIM, the most important newsflow usually covers development milestones, trial progress, partnering discussions and funding. Where a company has adopted a new identity or completed a corporate transaction, its announcements around that event explain the deal, any associated fundraising, changes to the board and the updated strategy. These disclosures form the foundation for tracking how the business is progressing over time.
Financial and dividend picture
Early-stage therapeutics businesses typically do not generate meaningful recurring revenue and rely on share placings, grants or partnership payments to finance development and clinical work. Dividends are uncommon for companies at that stage. The key financial measures are the cash position, the rate of spending and the resulting cash runway, along with any going concern disclosures in the accounts. Licensing deals can bring upfront and milestone payments that help extend that runway without the same degree of dilution.
Sector and index context
Biotechnology and pharmaceutical development companies form a notable part of AIM, which has long served as a funding venue for early-stage science businesses. As a member of the FTSE AIM All Share Index, Coiled Therapeutics sits within a benchmark dominated by small and micro-cap companies, where trading can be thin and share prices volatile. Funding conditions for smaller life-science companies have been challenging in recent years, and sentiment towards the sector can shift quickly with clinical data, partnering news and broader risk appetite.
Key risks
The main risks for any early-stage therapeutics company include clinical trial failure, regulatory setbacks, delays to development timelines and the need for repeated fundraising, which can dilute shareholders. Where a company has recently changed its identity, there may also be integration risk, limited operating history under the new strategy and a smaller body of published information for investors to assess. Low liquidity in AIM shares can amplify price moves in either direction.
What to watch next
Investors will watch for a clear account of the company's pipeline and priorities in its announcements and accounts. After that, the key items to monitor would typically include development milestones, any trial readouts, partnership or licensing agreements, fundraising announcements and changes to the board or advisers. Scheduled results and annual general meeting statements are also useful checkpoints for gauging the progress of Coiled Therapeutics (LSE:COIL) and the strength of its funding position relative to its development plans.
_11_16_2026_14_47_34_233787.jpg)





Please wait processing your request...